GNTA will begin to take its story to investors in NE.
Leerink Swann & Company Announces Its Platinum Co-sponsorship of the First "Mass Opportunities: a Biotechnology Investment Conference"
BOSTON--(BW HealthWire)--October 7, 1999--
Inaugural Investment Conference Organized By Massachusetts
Biotechnology Council 58 Biotechnology Companies To Be Highlighted at
Cambridge Conference October 18-19 at University Park Hotel at MIT
Leerink Swann & Company, a Boston-based investment banking and
asset management firm with a unique expert equity research group
specializing in biotech, pharmaceuticals and medical devices, today
announced its platinum-level sponsorship of "Mass Opportunities: A
Biotechnology Investment Conference," the first investment conference
to highlight Massachusetts-based biotechnology companies.
Jeffrey A. Leerink, President, Leerink Swann, said, "As a firm
providing leading-edge research on biotechnology, pharmaceutical and
healthcare advances, we are proud to support and sponsor the first
bio-tech investment conference to spotlight exclusively biotech
innovation resident in Massachusetts. Of the 58 companies
participating in the conference, we are sponsoring panel sessions
featuring well-known firms, such as Vertex Pharmaceuticals (VRTX) and
Transkaryotic Therapies (TKTX). In addition biotechnology heavyweights
such as Biogen (BGEN), Genzyme (GENZ) and Sepracor, Inc. (SEPR) will
address their prospects for the near and longer term.
"Massachusetts is an incubator for internationally known
biotechnology and healthcare companies. In fact, more than 250 biotech
companies are headquartered in Massachusetts, and the market
capitalization of these publicly-traded companies totals approximately
$29 billion," Mr. Leerink said. "This conference is timely, and Mass
Opportunities is the first showcase to spotlight many of the
world-class entrepreneurial biotechnology stars and startups
Massachusetts has to offer. Through our platinum sponsorship, Leerink
Swann & Company encourages investor interest in these biotech and
biomedical firms and urges support of this unique investment
conference," he added.
Leerink Swann, through its affiliate MEDACorp, has a unique
network of more than 350 biomedical professionals in the field --
physicians, clinician and researchers -- whose assessments augment the
analysis of the firm's research group.
The format of the Mass Opportunities conference will include
investor sessions focused on industry topics including the
perspectives of analysts, clinicians and/or specialists. Specific
investor sessions will cover cancer, drug discovery, drug delivery,
tissue repair, immunotherapeutics and infectious disease. There also
will be individual company presentations as well as a roundtable of
leading portfolio managers discussing "Institutional Investment
Strategies for Biotechnology."
Companies participating in the conference include: Advanced Inc.;
Anika Therapeutics, Inc. (ANIK); Aquila Biopharmaceuticals, Inc.
(AQLA); ArQule, Inc.(ARQL); AVANT Immunotherapeutics Inc. (AVAN);
Biogen, Inc. (BGEN); Biopure(R) Corporation (BPUR); BioTransplant,
(BTRN); Boston BioMedica, Inc. (BBII); Cambridge NeuroScience, (CNSI);
Circe Biomedical, Inc.; Collgard Biopharmaceuticals; Control Delivery
Systems; CpG Pharmaceuticals, Inc.; Cubist Diatide, Inc. (DITI);
Eligix, Inc.; Epic Therapeutics, Inc.; EPIX Medical, Inc. (EPIX);
EXACT Laboratories, Inc.; Genaissance Pharmaceuticals, Inc.; Genetix
Pharmaceuticals, Inc.; Genome Therapeutics Corporation (GENE); Genta,
Inc. (GNTA); Genzyme General Corporation (GENZ); Genzyme Molecular
Oncology (GZMO); Genzyme Surgical Products (GZSP); Genzyme Tissue
Repair (GXTR); Genzyme Transgenics Corporation (GZTC); Hybridon,
Inc.(HYBN.OB); ImmunoGen, Inc. (IMGN); InfiMed, Inc.; Kinetix
Pharmaceuticals, Inc.; LeukoSite, Inc. (LKST); Millenium
Pharmaceuticals, Inc. (MLNM); Mitotix, Inc.; Neurogen Corporation
(NRGN); Ontogeny, Inc.; Organogenesis, Inc. (ORG); OXiGENE, Inc.
(OXGN); Paratek Pharmaceuticals, Inc.; Periodontix, Inc.; PRAECIS
PHARMACEUTICALS, Inc; Repligen Corporation (RGEN); Reprogenesis; Safe
Science, Inc. (SAFS); Schafer Corporation; SCRIPTGEN Pharmaceuticals,
Inc.; Sepracor, Inc (SEPR); Sequitur, Inc.; Surgical Sealants, Inc.;
Therion Biologics Corporation; Transkaryotic Therapies, Inc. (TKTX);
TransXenoGen Inc.; Vertex Pharmaceuticals Inc. (VRTX); and ZYCOS Inc.
Organized by the Massachusetts Biotechnology Council, The Mass
Opportunities investment conference is scheduled for October 18-19 at
the University Park Hotel at MIT, Cambridge, Massachusetts. To
register for this conference, visit the Massachusetts Opportunities
Conference Web page (http://www.massopps.com) or contact Sarah Manning
at the Massachusetts Biotechnology Council at: (617) 577-8198, or by
e-mail (sarah-manning@massbio.org).
The Massachusetts Biotechnology Council is a not-for-profit
association representing more than 250 biotechnology companies,
academic institutions, contract research organizations, and industry
service providers. MBC members further the understanding of living
systems, and use advanced technologies to solve problems and develop
products for healthcare, agricultural, marine, industrial and
environmental applications.
Also supporting the October 18th Mass Opportunities Conference as
Platinum-sponsors are: Boston -based investment advisors Adams
Harkness & Hill; Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., a
Boston-based law firm with a biotech specialty group; and the
University of Massachusetts.
CONTACT:
Jon A. Civitarese Leo Murray or Ray McNulty
Leerink Swann & Company The Dilenschneider Group
Tel: 617-918-4814 Tel: 212-922-0900
Fax: 617-918-4914 Fax: 212-922-0971
E-mail: jonc@leerink.com |
